Short Interest in eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Expands By 8.5%

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 345,200 shares, a growth of 8.5% from the March 15th total of 318,100 shares. Based on an average daily trading volume, of 358,000 shares, the short-interest ratio is presently 1.0 days. Currently, 10.7% of the company’s stock are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Investments LP purchased a new stake in eFFECTOR Therapeutics during the third quarter worth about $27,000. Renaissance Technologies LLC acquired a new position in eFFECTOR Therapeutics in the second quarter valued at approximately $42,000. State Street Corp acquired a new stake in shares of eFFECTOR Therapeutics in the first quarter valued at approximately $68,000. Sonora Investment Management Group LLC purchased a new stake in shares of eFFECTOR Therapeutics during the third quarter worth approximately $75,000. Finally, Northern Trust Corp raised its stake in shares of eFFECTOR Therapeutics by 336.8% during the fourth quarter. Northern Trust Corp now owns 160,812 shares of the company’s stock worth $75,000 after purchasing an additional 123,998 shares during the last quarter. Institutional investors and hedge funds own 57.67% of the company’s stock.

eFFECTOR Therapeutics Stock Down 2.5 %

Shares of NASDAQ:EFTR traded down $0.05 during trading on Wednesday, hitting $1.94. 50,438 shares of the stock traded hands, compared to its average volume of 338,898. The company has a market cap of $7.16 million, a price-to-earnings ratio of -0.12 and a beta of 0.52. The company has a fifty day moving average price of $10.88 and a two-hundred day moving average price of $12.10. eFFECTOR Therapeutics has a 52-week low of $1.83 and a 52-week high of $37.00.

eFFECTOR Therapeutics (NASDAQ:EFTR) last announced its earnings results on Monday, March 25th. The company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.73) by ($0.69). On average, equities research analysts predict that eFFECTOR Therapeutics will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of eFFECTOR Therapeutics in a report on Thursday, March 28th.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.